Indian equity markets show a mixed but improving consumption trend, with selective FMCG and premium retail outperforming. Page Industries i...

Drug maker Cipla reported a 17.4% year-on-year (YoY) jump in net profit to Rs 1,178 crore in Q1FY25, led by strong US, India and South Afri...

Cipla plans acquisitions and inorganic partnerships in the US market while strengthening its presence in the domestic market. The company a...

Samina Hamied, executive vice-chairperson of Cipla, announced her decision to step down from her executive role due to personal and family ...

Drug maker Cipla reported a 33% year-on-year (YoY) jump in net profit to Rs 1049 crore in Q3FY24, led by strong US and India sales momentum.

Cipla boosts investment in GoApptiv with Rs. 42 crore infusion, raising its stake to 22.99%. This marks their third investment in the digit...

"Cipla historically has always been a big respiratory and acute player but not that big in the diabetes area," said Umang Vohra, managing d...

“I am humbled and honoured to receive the ET’s Businesswoman of the Year Award. This recognition belongs to each and every one of our 25,00...

Umang Vohra, MD and Global CEO, Cipla, said, "Cipla has been working relentlessly to ensure accessibility to treatments in this fight again...

"As part of this agreement, Cipla will be responsible for distribution of the COVID-19 rapid antibody kit that will be manufactured by Mult...

Cipla has said it is not "compelled" to go in for major M&As, preferring instead a semi-inorganic route to expand its global footprint.

The pharma major is expected to invest nearly Rs 1,030 crore over next few years for launch and development of new drugs as part of its glo...

The company will provide high quality affordable medicines to British National Health Service (NHS).

As part of its global expansion, Cipla had completed the buyout of South African pharma firm Cipla Medpro for Rs 2,707 crore last year.

As part of its global expansion, Cipla has been active in acquisitions. Last year, it completed the buyout of South African pharma firm, sa...

"The consideration payable for the transaction is $14 million," the filing said, adding that the proposed acquisition was subject to regula...

Cipla, India's second-largest drug maker, has hired Teva's former vice-president Frank Pieters to spearhead its European respiratory busine...